Integra LifeSciences (IART) Expected to Announce Earnings on Thursday

Integra LifeSciences (NASDAQ:IART) will likely be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $414.3080 million for the quarter. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS.Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $415.61 million for the quarter, compared to analysts’ expectations of $395.06 million. During the same period in the previous year, the company posted $0.63 earnings per share. Integra LifeSciences’s revenue was down .6% compared to the same quarter last year. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $15.56 on Wednesday. The firm has a fifty day moving average of $14.78 and a 200-day moving average of $13.89. Integra LifeSciences has a 52-week low of $11.06 and a 52-week high of $27.13. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $1.21 billion, a P/E ratio of -2.38 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Citigroup reissued a “sell” rating and issued a $12.00 price objective (up from $10.00) on shares of Integra LifeSciences in a research report on Tuesday, October 7th. Truist Financial set a $15.00 target price on Integra LifeSciences and gave the company a “hold” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Integra LifeSciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $16.17.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. grew its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after acquiring an additional 6,814 shares in the last quarter. Amundi increased its position in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock worth $150,000 after purchasing an additional 11,004 shares during the last quarter. State of Wyoming raised its stake in shares of Integra LifeSciences by 84.0% in the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company’s stock valued at $159,000 after purchasing an additional 5,914 shares in the last quarter. Finally, Humankind Investments LLC bought a new position in shares of Integra LifeSciences during the second quarter worth about $160,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.